Background: Preclinical studies have suggested concurrent non-antineoplastic medication use may impact pancreatic cancer. We performed an analysis to test this effect on pancreatic cancer outcome. Methods: Data from the Surveillance, Epidemiology and End Results (SEER)-Medicare with available part D data between 2006 and 2009 were analyzed. Cases with non-adenocarcinoma histology, autopsy only and death certificate only data were excluded. Drug use was defined as 1) having two prescriptions filled within 12 months of pancreatic cancer diagnosis (2rx/1yr) or 2) ever use. The following medication groups were analyzed: betablocker, statin, insulin, metformin, thiazolidinedione, warfarin and heparin. The primary end point was overall survival. Univariate analysis was performed to test the association of each medication class with survival. Stepwise Cox proportional hazard models were was employed to adjust for each medication group as well as age, gender, stage, site, race and Charlson comorbidity score. Results: There were 13,702 cases which met inclusion criteria and had available Part D data. There were 42.48% males, 77.07% were white and 34.00%had diabetes. Medication use and hazard ratio are summarized in table 1. On cox proportional hazard modeling beta blocker, heparin, insulin warfarin (2rx/1y) and betablocker, heparin, insulin (ever use) were associated were significantly associated with improved outcome (p < 0.05). Conclusions: Concurrent medication use, particularly betablockers, heparin and insulin may have an effect on pancreatic cancer outcome. Diabetes medications (metformin, TZD) did not have an impact in the multivariable model. This pharmacoepidemiological study adds to the interest in exploring use of concurrent medications in pancreatic cancer.